APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adeno-Associated Virus (AAV) Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Adeno-Associated Virus (AAV) Gene Therapy Market Analysis and Forecast 2026-2032

12 August 2026186 pages

Choose your research edition.

Industry ResearchAdeno-Associated Virus (AAV) Gene Therapy Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Adeno-Associated Virus (AAV) Gene Therapy Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Adeno-Associated Virus (AAV) Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adeno-Associated Virus (AAV) Gene Therapy Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Adeno-Associated Virus (AAV) Gene Therapy Market Analysis and Forecast 2026-2032186 pages · $4,950 USD

Market perspective

The global Adeno-Associated Virus (AAV) Gene Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Adeno-Associated Virus (AAV) Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Adeno-Associated Virus (AAV) Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Adeno-Associated Virus (AAV) Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Adeno-Associated Virus (AAV) Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Adeno-Associated Virus (AAV) Gene Therapy include AGC Biologics, StrideBio, SIRION Biotech, Neurophth Biotechnology, Belief BioMed, BiBo Biopharma Engineering Co., LTD., Beihai Kangcheng, PackGene Biotech and Sarepta Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Adeno-Associated Virus (AAV) Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Adeno-Associated Virus (AAV) Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Adeno-Associated Virus (AAV) Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Adeno-Associated Virus (AAV) Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Adeno-Associated Virus (AAV) Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Adeno-Associated Virus (AAV) Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.

Adeno-Associated Virus (AAV) Gene Therapy Segment by Company

AGC Biologics

StrideBio

SIRION Biotech

Neurophth Biotechnology

Belief BioMed

BiBo Biopharma Engineering Co., LTD.

Beihai Kangcheng

PackGene Biotech

Sarepta Therapeutics

Carbon BioSciences

Kelonia Therapeutics

Roche

Remedium Bio

Creative Biolabs

Affinia Therapeutics

Spark Therapeutics

Adeno-Associated Virus (AAV) Gene Therapy Segment by Type

Luxturna

Zolgensma

Others

Adeno-Associated Virus (AAV) Gene Therapy Segment by Application

Central Nervous System Diseases

Ocular Diseases

Liver-directed Diseases

Other Hereditary Diseases

Adeno-Associated Virus (AAV) Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adeno-Associated Virus (AAV) Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adeno-Associated Virus (AAV) Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adeno-Associated Virus (AAV) Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Adeno-Associated Virus (AAV) Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Adeno-Associated Virus (AAV) Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adeno-Associated Virus (AAV) Gene Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Luxturna Major Player Table 3. Zolgensma Major Player Table 4. Others Major Player Table 5. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Central Nervous System Diseases Major Player Table 7. Ocular Diseases Major Player Table 8. Liver-directed Diseases Major Player Table 9. Other Hereditary Diseases Major Player Table 10. Adeno-Associated Virus (AAV) Gene Therapy Industry Trends Table 11. Adeno-Associated Virus (AAV) Gene Therapy Industry Drivers Table 12. Adeno-Associated Virus (AAV) Gene Therapy Industry Opportunities and Challenges Table 13. Adeno-Associated Virus (AAV) Gene Therapy Industry Restraints Table 14. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region (2021-2026) Table 17. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region (2027-2032) Table 19. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Players (2021-2026) Table 21. Global Adeno-Associated Virus (AAV) Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Adeno-Associated Virus (AAV) Gene Therapy Key Players Headquarters & Area Served Table 23. Global Adeno-Associated Virus (AAV) Gene Therapy Players, Product Type & Application Table 24. Global Adeno-Associated Virus (AAV) Gene Therapy Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Adeno-Associated Virus (AAV) Gene Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Type (2021-2026) Table 31. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Type (2027-2032) Table 32. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Application (2021-2026) Table 36. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Application (2027-2032) Table 37. AGC Biologics Company Information Table 38. AGC Biologics Business Overview Table 39. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 41. AGC Biologics Recent Development Table 42. StrideBio Company Information Table 43. StrideBio Business Overview Table 44. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 46. StrideBio Recent Development Table 47. SIRION Biotech Company Information Table 48. SIRION Biotech Business Overview Table 49. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 51. SIRION Biotech Recent Development Table 52. Neurophth Biotechnology Company Information Table 53. Neurophth Biotechnology Business Overview Table 54. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 56. Neurophth Biotechnology Recent Development Table 57. Belief BioMed Company Information Table 58. Belief BioMed Business Overview Table 59. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 61. Belief BioMed Recent Development Table 62. BiBo Biopharma Engineering Co., LTD. Company Information Table 63. BiBo Biopharma Engineering Co., LTD. Business Overview Table 64. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 66. BiBo Biopharma Engineering Co., LTD. Recent Development Table 67. Beihai Kangcheng Company Information Table 68. Beihai Kangcheng Business Overview Table 69. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 71. Beihai Kangcheng Recent Development Table 72. PackGene Biotech Company Information Table 73. PackGene Biotech Business Overview Table 74. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 76. PackGene Biotech Recent Development Table 77. Sarepta Therapeutics Company Information Table 78. Sarepta Therapeutics Business Overview Table 79. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 81. Sarepta Therapeutics Recent Development Table 82. Carbon BioSciences Company Information Table 83. Carbon BioSciences Business Overview Table 84. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 86. Carbon BioSciences Recent Development Table 87. Kelonia Therapeutics Company Information Table 88. Kelonia Therapeutics Business Overview Table 89. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 91. Kelonia Therapeutics Recent Development Table 92. Roche Company Information Table 93. Roche Business Overview Table 94. Roche Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 96. Roche Recent Development Table 97. Remedium Bio Company Information Table 98. Remedium Bio Business Overview Table 99. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 101. Remedium Bio Recent Development Table 102. Creative Biolabs Company Information Table 103. Creative Biolabs Business Overview Table 104. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 106. Creative Biolabs Recent Development Table 107. Affinia Therapeutics Company Information Table 108. Affinia Therapeutics Business Overview Table 109. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 111. Affinia Therapeutics Recent Development Table 112. Spark Therapeutics Company Information Table 113. Spark Therapeutics Business Overview Table 114. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 116. Spark Therapeutics Recent Development Table 117. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 118. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 119. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 120. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 121. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 123. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 124. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 125. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 126. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 127. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 128. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 130. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 131. China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 132. China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 133. China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 134. China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 136. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 137. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 138. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 139. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Region (US$ Million) & (2021-2026) Table 141. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Region (US$ Million) & (2027-2032) Table 142. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 143. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 144. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 145. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 146. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 148. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Adeno-Associated Virus (AAV) Gene Therapy Image Figure 2. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Luxturna Image Figure 5. Zolgensma Image Figure 6. Others Image Figure 7. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 9. Central Nervous System Diseases Image Figure 10. Ocular Diseases Image Figure 11. Liver-directed Diseases Image Figure 12. Other Hereditary Diseases Image Figure 13. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (US$ Million) & (2021-2032) Figure 14. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Adeno-Associated Virus (AAV) Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Type (2021-2032) Figure 21. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Application (2021-2032) Figure 24. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032) Figure 26. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032) Figure 27. North America Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Country (2021-2032) Figure 28. United States Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032) Figure 33. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032) Figure 34. Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Country (2021-2032) Figure 35. Germany Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032) Figure 45. China Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032) Figure 46. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032) Figure 48. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032) Figure 49. Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Region (2021-2032) Figure 50. Japan Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032) Figure 58. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032) Figure 59. SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Country (2021-2032) Figure 60. Brazil Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Adeno-Associated Virus (AAV) Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Luxturna
  • Zolgensma
  • Others
Applications
  • Central Nervous System Diseases
  • Ocular Diseases
  • Liver-directed Diseases
  • Other Hereditary Diseases
Companies covered
  • AGC Biologics
  • StrideBio
  • SIRION Biotech
  • Neurophth Biotechnology
  • Belief BioMed
  • BiBo Biopharma Engineering Co., LTD.
  • Beihai Kangcheng
  • PackGene Biotech
  • Sarepta Therapeutics
  • Carbon BioSciences
  • Kelonia Therapeutics
  • Roche
  • Remedium Bio
  • Creative Biolabs
  • Affinia Therapeutics
  • Spark Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Adeno-Associated Virus (AAV) Gene Therapy Market by Type
  3. 1.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Luxturna
  5. 1.2.3 Zolgensma
  6. 1.2.4 Others
  7. 1.3 Adeno-Associated Virus (AAV) Gene Therapy Market by Application
  8. 1.3.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Central Nervous System Diseases
  10. 1.3.3 Ocular Diseases
  11. 1.3.4 Liver-directed Diseases
  12. 1.3.5 Other Hereditary Diseases
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Adeno-Associated Virus (AAV) Gene Therapy Market Dynamics
  1. 2.1 Adeno-Associated Virus (AAV) Gene Therapy Industry Trends
  2. 2.2 Adeno-Associated Virus (AAV) Gene Therapy Industry Drivers
  3. 2.3 Adeno-Associated Virus (AAV) Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Adeno-Associated Virus (AAV) Gene Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Perspective (2021-2032)
  2. 3.2 Global Adeno-Associated Virus (AAV) Gene Therapy Growth Trends by Region
  3. 3.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Players
  2. 4.1.1 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Adeno-Associated Virus (AAV) Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Adeno-Associated Virus (AAV) Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Adeno-Associated Virus (AAV) Gene Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Adeno-Associated Virus (AAV) Gene Therapy Players, Product Type & Application
  8. 4.5 Global Adeno-Associated Virus (AAV) Gene Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market CR5 and HHI
  11. 4.6.3 2025 Adeno-Associated Virus (AAV) Gene Therapy Tier 1, Tier 2, and Tier 3
5 Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type
  1. 5.1 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Type (2021-2032)
6 Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application
  1. 6.1 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AGC Biologics
  2. 7.1.1 AGC Biologics Company Information
  3. 7.1.2 AGC Biologics Business Overview
  4. 7.1.3 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  6. 7.1.5 AGC Biologics Recent Developments
  7. 7.2 StrideBio
  8. 7.2.1 StrideBio Company Information
  9. 7.2.2 StrideBio Business Overview
  10. 7.2.3 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  12. 7.2.5 StrideBio Recent Developments
  13. 7.3 SIRION Biotech
  14. 7.3.1 SIRION Biotech Company Information
  15. 7.3.2 SIRION Biotech Business Overview
  16. 7.3.3 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  18. 7.3.5 SIRION Biotech Recent Developments
  19. 7.4 Neurophth Biotechnology
  20. 7.4.1 Neurophth Biotechnology Company Information
  21. 7.4.2 Neurophth Biotechnology Business Overview
  22. 7.4.3 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  24. 7.4.5 Neurophth Biotechnology Recent Developments
  25. 7.5 Belief BioMed
  26. 7.5.1 Belief BioMed Company Information
  27. 7.5.2 Belief BioMed Business Overview
  28. 7.5.3 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  30. 7.5.5 Belief BioMed Recent Developments
  31. 7.6 BiBo Biopharma Engineering Co., LTD.
  32. 7.6.1 BiBo Biopharma Engineering Co., LTD. Company Information
  33. 7.6.2 BiBo Biopharma Engineering Co., LTD. Business Overview
  34. 7.6.3 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  36. 7.6.5 BiBo Biopharma Engineering Co., LTD. Recent Developments
  37. 7.7 Beihai Kangcheng
  38. 7.7.1 Beihai Kangcheng Company Information
  39. 7.7.2 Beihai Kangcheng Business Overview
  40. 7.7.3 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  42. 7.7.5 Beihai Kangcheng Recent Developments
  43. 7.8 PackGene Biotech
  44. 7.8.1 PackGene Biotech Company Information
  45. 7.8.2 PackGene Biotech Business Overview
  46. 7.8.3 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  48. 7.8.5 PackGene Biotech Recent Developments
  49. 7.9 Sarepta Therapeutics
  50. 7.9.1 Sarepta Therapeutics Company Information
  51. 7.9.2 Sarepta Therapeutics Business Overview
  52. 7.9.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  54. 7.9.5 Sarepta Therapeutics Recent Developments
  55. 7.10 Carbon BioSciences
  56. 7.10.1 Carbon BioSciences Company Information
  57. 7.10.2 Carbon BioSciences Business Overview
  58. 7.10.3 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  60. 7.10.5 Carbon BioSciences Recent Developments
  61. 7.11 Kelonia Therapeutics
  62. 7.11.1 Kelonia Therapeutics Company Information
  63. 7.11.2 Kelonia Therapeutics Business Overview
  64. 7.11.3 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  66. 7.11.5 Kelonia Therapeutics Recent Developments
  67. 7.12 Roche
  68. 7.12.1 Roche Company Information
  69. 7.12.2 Roche Business Overview
  70. 7.12.3 Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  72. 7.12.5 Roche Recent Developments
  73. 7.13 Remedium Bio
  74. 7.13.1 Remedium Bio Company Information
  75. 7.13.2 Remedium Bio Business Overview
  76. 7.13.3 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  78. 7.13.5 Remedium Bio Recent Developments
  79. 7.14 Creative Biolabs
  80. 7.14.1 Creative Biolabs Company Information
  81. 7.14.2 Creative Biolabs Business Overview
  82. 7.14.3 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  84. 7.14.5 Creative Biolabs Recent Developments
  85. 7.15 Affinia Therapeutics
  86. 7.15.1 Affinia Therapeutics Company Information
  87. 7.15.2 Affinia Therapeutics Business Overview
  88. 7.15.3 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  90. 7.15.5 Affinia Therapeutics Recent Developments
  91. 7.16 Spark Therapeutics
  92. 7.16.1 Spark Therapeutics Company Information
  93. 7.16.2 Spark Therapeutics Business Overview
  94. 7.16.3 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  96. 7.16.5 Spark Therapeutics Recent Developments
8 North America
  1. 8.1 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue (2021-2032)
  2. 8.2 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country
  11. 8.6.1 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue (2021-2032)
  2. 9.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country
  11. 9.6.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Adeno-Associated Virus (AAV) Gene Therapy Revenue (2021-2032)
  2. 10.2 China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032)
  5. 10.3 China Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032)
  9. 10.5 China Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue (2021-2032)
  2. 11.2 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country
  11. 11.6.1 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country
  11. 12.6.1 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Adeno-Associated Virus (AAV) Gene Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst